Table 2

Baseline Characteristics of the Study Population

Radiation Patients
(n = 263)
Control Patients
(n = 526)
p Value
Age, yrs49.9 ± 11.049.7 ± 10.80.77
Male121 (46.0)228 (43.4)0.49
BMI, kg/m226.3 ± 5.627.7 ± 6.00.002
Cardiovascular risk factors
 Hypertension78 (30.0)171 (32.5)0.47
 Diabetes mellitus14 (5.3)34 (6.5)0.64
 Hyperlipidemia130 (49.4)203 (38.6)0.005
 Family history of IHD90 (46.2)174 (45.9)1.00
 Smoking history13 (4.9)43 (8.2)0.11
 Congestive heart failure26 (9.9)60 (11.4)0.55
 Ischemic heart disease41 (15.6)52 (9.9)0.03
 Morise score9 (3 to 12)9 (4 to 12)0.92
Cardiovascular medications
 Beta-blocker58 (22.1)120 (22.8)0.86
 Calcium-channel blocker18 (6.8)41 (7.8)0.70
 ACE inhibitor33 (12.6)79 (15.0)0.39
 Diuretic23 (8.8)54 (10.3)0.53
 Statin96 (36.5)146 (27.8)0.01
Age at time of RT, yrs30.0 ± 12.4
Interval from RT to ETT, yrs19 (12–26)
Total radiation dose, Gy38 (36–40)
Adjuvant anthracycline chemotherapy121 (46.0)
LV ejection fraction, %59.0 ± 5.3

Values are mean ± SD, n (%), or median (interquartile range).

ACE = angiotensin-converting enzyme; BMI = body mass index; ETT = exercise treadmill test; IHD = ischemic heart disease; LV = left ventricle; RT = radiation therapy.

  • LV ejection fraction available for 226 of 263 (86%) RT patients.